LUGPA Annual Meeting

Articles

In this interview, Jason M. Hafron, MD, discusses the “buzz” surrounding the meeting and touches on clinical topics including germline and somatic testing, PARP inhibitors, and mitomycin-containing reverse thermal gel (Jelmyto).

Dr. Hafron on LUGPA 2021 and the rapidly evolving prostate and bladder cancer treatment landscapes

Videos

“[Out] of everything going on, this is probably 1 of the most exciting areas in prostate cancer,” says Jason M. Hafron, MD.

A urologist gives his take on PSMA in prostate cancer

"It depends on how you're paid and the structure of the compensation model," says Jennifer Miles-Thomas, MD, FPMRS. 

Dr. Jennifer Miles-Thomas discusses the gender pay gap in urology

“I think as our understanding of mutations [and] our understanding the PARP inhibitors [grows], if the data pans out, we'll be using these earlier and earlier in patients, which I think we'll [will allow us to] see probably more benefit,” says Jason M. Hafron, MD. 

Dr. Hafron on PARP inhibitors in prostate cancer

“The notion that we have to see a patient in front of us every time in order to have a billable encounter is antiquated,” says Gary Kirsh, MD.

Dr. Kirsh on telehealth reimbursement for urologists

Jennifer Miles-Thomas, MD, FPMRS, explains why urology practices need to have female urologists and approaches for recruiting them.

Strategies for recruiting female urologists to your practice

“In our practices right now, the biggest challenge we have is being acquired by hospital systems,” says R. Jonathan Henderson, MD. 

LUGPA President Dr. R. Jonathan Henderson on top challenges faced by urology practices

Steven A. Kaplan, MD, highlights the latest developments in BPH and previews what's on the horizon in the space. 

Dr. Kaplan weighs in on BPH developments at LUGPA 2021

“The future in bladder cancer [and] prostate cancer is really exploding. The therapeutics are coming faster than we ever thought,” says Jason M. Hafron, MD.

Dr. Hafron on the “buzz” surrounding the 2021 LUGPA annual meeting

“Telehealth really helped salvage some of the care that was deferred during the early part of the pandemic, and it’s really here to stay,” says Chad Ellimoottil, MD, MS.